idalab seminar - The Target-Disease Model Is Dead. AI Can’t Fix It — Yet

This erodes statistical power, drives combination therapies, inflates trial costs, and pushes payers into an affordability crisis just as the patent super-cliff removes more than $200bn in protected revenue by 2030.

AI can accelerate exploitation of existing paradigms — predicting responders, validating targets, ranking combinations, and reducing clinical waste — but it remains bounded by the known and cannot yet originate new biological frameworks. In other words, AI can navigate the rubble of the old paradigm, but it cannot rebuild the edifice that used to sit on it.

The strategic consequence is profound: innovation shifts from discovering single molecules to navigating combinatorial biological spaces under brutal economic constraints. In his talk, Matthias P. Schönermark (Chief Strategy Officer at Kintiga) will map why the old model died, where AI actually creates value today, and what a viable playbook for post-blockbuster biopharma might look like.

Everyone is welcome, registration is required via Luma.